GlaxoSmithKline gets AstraZeneca to finally release former executive Miels, in two more months

AstraZeneca has reached an agreement with GlaxoSmithKline that will allow former European business head Luke Miels to take the top pharma job with its competitor in September.

Six months after accepting a job with GlaxoSmithKline, former AstraZeneca executive Luke Miels has learned he will finally get to take on his new duties—just not until September.

GSK indicated that it has reached an agreement with its U.K. peer, Reuters reports, and that Miels will start on Sept. 4 as president of its pharma division. A GSK spokeswoman confirmed the report but said the company would not disclose terms of the settlement.  

RELATED: Disgruntled AstraZeneca sues former executive Luke Miels for jumping to GlaxoSmithKline post 


Use Serialization Data to Maximize Performance and Minimize Risks

Wednesday, March 18 | 11am ET / 8am PT

Serialized products generate a wealth of data as they move through the supply chain. What if you could access and analyze this data to gain operational visibility and powerful business insight? It’s time to put your serialization investment to work for you.

AstraZeneca had sued after Miels gave notice in January, seeking an order to force him to “abide by the terms of his contract of employment.”  He was executive vice president of AstraZeneca’s European business.

Miels was recruited by Emma Walmsley, who took over as GSK’s CEO only in April. With R&D and commercial experience from stints at AstraZeneca, Roche and Sanofi, Miels is seen as a key appointment given that her experience is in marketing and consumer products. Some investors have grumbled that her experience is not sufficiently deep on the branded drug side, a division that accounted for about £15 billion ($19.1 billion) in sales, more than half of its 2016 revenues of £27.9 billion ($35.5 billion).

RELATED: Could third time be the charm for Advair copycats? Novartis’ Sandoz aims to find out 

Miels will have his hands full when he finally gets to GSK. This may be the year that its top-selling Advair succumbs to generic competition, which the company has said could trim about 45% in sales off the $2.3 billion respiratory drug.  

The company also has one of the lowest R&D budgets in terms of percentage of revenue among its peers, with much of its late-stage work focused on vaccines and respiratory after trading off much of its late-stage and marketed cancer assets to Novartis a few years back.

Suggested Articles

Several of the industry's top players had a strong performance in the fourth quarter, growing revenues at high single digits. Others? Not so much.

Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.

An FDA approval of Lilly’s Cyramza combo would pit it against AZ's Tagrisso, which has charted impressive survival gains in EGFR-positive lung cancer.